NCT01476449View on ClinicalTrials.gov

Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Diabetic RetinopathyMacular Edema
Interventions
DRUG

Ranibizumab

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

DRUG

Ranibizumab

Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.

Trial Locations (2)

33711

Retina Vitreous Associates of Florida, St. Petersburg

33756

Retina Vitreous Associates of Florida, Clearwater

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Retina Vitreous Associates of Florida

OTHER

NCT01476449 - Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema | Biotech Hunter | Biotech Hunter